Intra-Cellular Therapies reported Q4 2024 financial results, featuring a 51% increase in CAPLYTA net product sales to $199.2 million compared to the same period in 2023. The FDA accepted the sNDA submission for lumateperone for adjunctive treatment of major depressive disorder (MDD).

Intra-Cellular Therapies announced its Q3 2024 financial results, highlighted by a 39% increase in Caplyta net product sales, reaching $175.2 million compared to the same period in 2023. The company is also on track to submit its sNDA for adjunctive treatment of MDD and raised its full year 2024 net product sales guidance for Caplyta to $665 to $685 million.

Intra-Cellular Therapies announced its Q2 2024 financial results, highlighted by a 46% increase in CAPLYTA net product sales to $161.3 million compared to the same period in 2023. The company also reported a net loss of $16.2 million, an improvement from the $42.8 million net loss in Q2 2023. CAPLYTA's strong prescription uptake continues with a 36% increase versus the same period in 2023. The company raised its full year 2024 CAPLYTA net product sales guidance to $650 to $680 million.

Intra-Cellular Therapies announced its Q1 2024 financial results, featuring a 53% increase in CAPLYTA net product sales, reaching $144.8 million compared to $94.7 million in Q1 2023. The company also reported positive Phase 3 results for lumateperone in treating major depressive disorder (MDD).

Intra-Cellular Therapies reported a net loss of $28.6 million for Q4 2023, with CAPLYTA net product sales reaching $131.5 million, a 50% increase over Q4 2022. The company's full-year revenue for 2023 was $464.4 million, including $462.2 million in CAPLYTA net product sales, representing an 86% year-over-year growth. The company anticipates CAPLYTA 2024 net product sales of $645 to $675 million.

Intra-Cellular Therapies reported a strong third quarter with total revenues increasing to $126.2 million, driven by a 75% increase in Caplyta net product sales to $125.8 million. The company raised its full year 2023 Caplyta net product sales guidance to $460 to $470 million.

Intra-Cellular Therapies reported a strong second quarter in 2023, with total revenues increasing to $110.8 million, driven by a 100% increase in CAPLYTA net product sales compared to the same period in 2022. The company raised its full year 2023 CAPLYTA net product sales guidance to $445 to $465 million.

Intra-Cellular Therapies reported Q1 2023 financial results, highlighted by a significant increase in total revenues to $95.3 million compared to $35.0 million in the same period of 2022. The growth was primarily driven by net product sales of CAPLYTA, which reached $94.7 million, representing a 173% increase year-over-year. The company also announced positive results from a clinical study evaluating lumateperone in patients with mixed features in major depressive disorder and bipolar depression.

Intra-Cellular Therapies reported a net loss of $44.0 million for Q4 2022, with CAPLYTA net product sales reaching $87.4 million, a 243% increase year-over-year. The company's full-year revenue for 2022 was $250.3 million, driven by CAPLYTA's strong performance.

Intra-Cellular Therapies reported a net loss of $53.5 million for Q3 2022. Total revenues were $71.9 million, with CAPLYTA net product revenues reaching $71.9 million, a 233% increase compared to Q3 2021. The company's cash, cash equivalents, and investment securities totaled $630.5 million.

Intra-Cellular Therapies reported a total revenue of $55.6 million for the second quarter of 2022, a 178% increase compared to the same period in 2021. CAPLYTA net product revenues were $55.1 million, representing a 190% increase year-over-year. The company's net loss for the quarter was $86.6 million.

Intra-Cellular Therapies reported a total revenue of $35 million for Q1 2022, a 120% increase compared to Q1 2021. CAPLYTA net product revenues were $34.8 million, representing a 123% increase year-over-year. The company's net loss was $72.1 million, and cash, cash equivalents, and investment securities totaled $773.2 million.

Intra-Cellular Therapies announced its Q4 and full-year 2021 financial results, marked by FDA approval of CAPLYTA for bipolar depression and significant revenue growth. Total Q4 revenues reached $25.7 million, a 106% increase year-over-year, with CAPLYTA net product revenues at $25.5 million, also a 106% increase. The company is advancing CAPLYTA development programs and other pipeline initiatives.

Intra-Cellular Therapies announced its Q3 2021 financial results, reporting a net loss of $76.9 million. Total revenues were $22.2 million, driven by CAPLYTA net product revenues of $21.6 million. The company continues to advance its development programs and prepare for the potential launch of CAPLYTA in bipolar depression.

Intra-Cellular Therapies reported total revenues of $20.0 million for the second quarter of 2021, compared to $1.9 million for the second quarter of 2020. CAPLYTA net product revenues were $19.0 million for the second quarter, a 22% increase from the prior quarter.

Intra-Cellular Therapies reported total revenues of $15.9 million for the first quarter of 2021, with CAPLYTA net product revenues reaching $15.6 million. The FDA accepted the sNDAs for lumateperone for bipolar depression treatment, setting a PDUFA target action date of December 17, 2021.

Intra-Cellular Therapies reported Q4 2020 financial results, featuring CAPLYTA net product revenues of $12.4 million and a 77% increase in total prescriptions compared to the previous quarter. The company is pursuing CAPLYTA label expansion and advancing its pipeline with ITI-1284.

Intra-Cellular Therapies reported net product sales of CAPLYTA for the third quarter of 2020 of approximately $7.4 million. The company is preparing sNDA for the treatment of bipolar depression for submission to the FDA and expanding lumateperone development in Major Depressive Disorder (MDD).

Intra-Cellular Therapies reported net product sales of CAPLYTA for the second quarter of 2020 of approximately $1.9 million. The Company reported a net loss of $63.7 million, or $0.96 per share.

Intra-Cellular Therapies reported net product sales of CAPLYTA of approximately $882,500 for the first quarter of 2020. The company's net loss was $47.4 million, or $0.73 per share.

Intra-Cellular Therapies reported a net loss of $40.6 million for the fourth quarter of 2019. The company is preparing for the commercial launch of CAPLYTA after its recent FDA approval.